Pathological Tumor and Lymph Node Responses After Neoadjuvant Immunochemotherapy in Initially-unresectable NSCLC
Launched by GUANGDONG PROVINCIAL PEOPLE'S HOSPITAL · Nov 24, 2022
Trial Information
Current as of January 13, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Patients with stage III NSCLC who received neoadjuvant immunochemotherapy.
- • early-stage NSCLC patients who were initially unresectable.
- • 18 years of age or older.
- • Karnofsky performance status (KPS) score of 100 or 90.
- Exclusion Criteria:
- • Patients with stage IV NSCLC
- • Patients with known ALK translocations or EGFR mutations.
- • Karnofsky performance status (KPS) score \<90.
Trial Officials
Guibin Qiao, MD
Study Director
Guangdong Provincial People's Hospital
About Guangdong Provincial People's Hospital
Guangdong Provincial People's Hospital is a leading tertiary healthcare institution located in Guangdong Province, China, renowned for its comprehensive medical services and advanced research capabilities. As a prominent clinical trial sponsor, the hospital is dedicated to advancing medical science through innovative research and the rigorous evaluation of new therapies and interventions. With a multidisciplinary team of experienced clinicians and researchers, the institution prioritizes patient safety and ethical standards while fostering collaborations with academic and industry partners to enhance healthcare outcomes and contribute to the global medical community.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Guangzhou, Guangdong, China
People applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Discussion 0
Related articles
Similar Trials